Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

108.60 -0.27 (-0.25%)
Official Closing Price Updated: 4:10 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,321,325
Open 109.50
Bid (Size) 108.37 (500)
Ask (Size) 109.30 (300)
Prev. Close 108.87
Today's Range 107.95 - 111.46
52wk Range 73.31 - 110.17
Shares Outstanding 2,531,374,696
Dividend Yield 3.13%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance
As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era
As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands... 
Via MarketMinute
Topics Economy

Performance

YTD
+2.0%
+2.0%
1 Month
+9.8%
+9.8%
3 Month
+24.0%
+24.0%
6 Month
+33.5%
+33.5%
1 Year
+8.9%
+8.9%

More News

Read More
News headline image
3 Drug Stocks to Buy at a Discount ↗
Via The Motley Fool
News headline image
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
Via PredictStreet
Topics Economy Initial Public Offering Intellectual Property
News headline image
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
From Merck & Co., Inc.
Via Business Wire
News headline image
Merck to Complete Acquisition of Cidara Therapeutics
From Merck Sharp & Dohme
Via Business Wire
News headline image
Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3
From Merck & Co., Inc.
Via Business Wire
News headline image
The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK ↗
Via Benzinga
News headline image
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗
Via The Motley Fool
Topics Stocks
News headline image
U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗
Via Stocktwits
Topics Government
News headline image
Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
News headline image
The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
BofA Unveils Q1 2026 Top Stock Picks: High-Conviction Bets on AI Infrastructure and Health Care Valuations
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Generating Yield in a Sideways Market: The Strategic Rise of Dow Jones Covered Call ETFs
Via MarketMinute
Topics ETFs Economy Regulatory Compliance
News headline image
Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30
Via MarketMinute
Topics Intellectual Property
News headline image
The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Top gainers and losers in the S&P500 index during Monday's after-hours session. ↗
Via Chartmill
News headline image
The Price of Prosperity: Navigating the S&P 500’s Historic Valuation Peak as 2026 Dawns
Via MarketMinute
Topics Artificial Intelligence Bonds Earnings
News headline image
3 Drug Stocks to Buy at a Discount ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit
Via PredictStreet
News headline image
Merck & Co. Inc. (NYSE:MRK) Emerges as a Top Quality Investing Candidate ↗
Via Chartmill

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 108.60
When was Merck & Co last traded?
The last trade of Merck & Co was at 01/07/26 04:10 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 274.91B
How many shares of Merck & Co are outstanding?
Merck & Co has 275B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.